Barclays raised the firm’s price target on Neurocrine to $145 from $125 and keeps an Overweight rating on the shares. The firm views 2024 as “the best setup in recent memory” for Neurocrine citing the “triple threat” of Ingrezza momentum, CAH progress, and muscarinic phase 2 data that is due.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NBIX:
